The U.S. Chamber submitted comments to the European Commission as it considers revisions and updates to its General Pharmaceuticals Legislation, which is Europe’s attempt to foster innovation, improve the resiliency of the healthcare sector in Europe, bolster supply chain security, and ensure access to innovative medicines across the EU. We encouraged the EU to do a better job of rewarding and prioritizing innovation, guarantee strong IP protections for manufacturers, and preserve open and integrated global supply chains rather than attempting to cut Europe off from the global economy in healthcare. We also focused on the importance of digital health and transatlantic coordination, including for research and pandemic response and recovery.
Recommended
International
IPEF and Biopharma Supply Chains: Facts, Goals, and Action
As representatives of the U.S. and the 13 other nations gather for negotiations on the Indo-Pacific Economic Framework (IPEF) in New Delhi in February, supply chain resilience will be one of the key issues on the agenda.
By John G. Murphy
International
Union Files Second Complaint Against VU Manufacturers Under USMCA
By Stephanie FergusonInternational
Moving Toward a More Prosperous U.S.-Japan Relationship
By Charles Freeman
View this online